🇺🇸 FDA
Patent

US 9663575

CD47 antibodies and methods of use thereof

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 9663575 (CD47 antibodies and methods of use thereof) held by Inhibrx, Inc. expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx, Inc.
Grant date
Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K39/39558, A61K45/06